KIYATEC develops patient-specific cancer therapy response testing using a 3D cell culture platform
KIYATEC develops patient-specific cancer therapy response testing using a 3D cell culture platform. The platform uses a patient's live tumor tissue to assess and predict how tumor cells respond to drug therapies, supporting personalized treatment decisions. The company also provides pharma and biotech partners with 3D cell culture services for drug discovery and development.
The top three firms on F4's Biotech & Life Sciences investor list.